Home Newsfeeds BMO Capital Maintains Outperform on Stride, Raises Price Target to $48

BMO Capital Maintains Outperform on Stride, Raises Price Target to $48

BMO Capital analyst Jeffrey Silber maintains Stride (NYSE:LRN) with a Outperform and raises the price target from $47 to $48.

byBenzinga Newsdesk

January 26, 2023

1 minute read

BMO Capital analyst Jeffrey Silber maintains Stride (NYSE:LRN) with a Outperform and raises the price target from $47 to $48.

EF Hutton Initiates Coverage On TCR2 Therapeutics with Hold Rating, Announces Price Target of $2

By Benzinga Newsdesk

January 5, 5:32 AM

EF Hutton analyst Tony Butler initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Hold rating and announces Price Target of $2.

TCRR

Horizon Therapeutics Options Trader Betting On A Major Dip For Stock By January 2024

By Priya Nigam

May 17, 8:14 AM

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) shares dropped sharply on Tuesday following a report suggesting the FTC is expected to file a complaint to block Amgen's

HZNP

Kineta Unveils New Data From VISTA-101 Clinical Trial Of KVA12123 At The Society For Immunotherapy Of Cancer’s 38th Annual Meeting

By Benzinga Newsdesk

November 6, 9:34 AM

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional PharmacokineticsBiomarker Results Demonstrate Robust VISTA Target

Biden Pressures Israel For Ceasefire, Signals Possible US Policy Shift; Netanyahu Stands Firm Against Iran

By Piero Cingari

April 4, 4:58 PM

U.S. President Biden urges Israel's Netanyahu to implement ceasefire in Gaza war, with emphasis on addressing humanitarian concerns and protecting aid workers.

EIS

BMO Capital Maintains Outperform on Stride, Raises Price Target to $48

Related Posts

EF Hutton Initiates Coverage On TCR2 Therapeutics with Hold Rating, Announces Price Target of $2

Horizon Therapeutics Options Trader Betting On A Major Dip For Stock By January 2024

Kineta Unveils New Data From VISTA-101 Clinical Trial Of KVA12123 At The Society For Immunotherapy Of Cancer’s 38th Annual Meeting

Biden Pressures Israel For Ceasefire, Signals Possible US Policy Shift; Netanyahu Stands Firm Against Iran